🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
October 7, 2026 at 11:46 AM
🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
October 7, 2026 at 10:10 AM
🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
BUY $LPCN (LPCN.O) [FDA] @ 10:11:29Z
October 7, 2026 at 10:11 AM
BUY $LPCN (LPCN.O) [FDA] @ 10:11:29Z
$LPCN — Health Canada approval of TLANDO drives LPCN stock surge, overshadowing long-term financial headwinds.
Health Canada approval of TLANDO for Canadian market.
https://market-scanner.net/tickers/LPCN.US
#ai #trading
Health Canada approval of TLANDO for Canadian market.
https://market-scanner.net/tickers/LPCN.US
#ai #trading
LPCN.US — AI analysis summary
Descriptive, non-directional summary of recent AI analyses.
market-scanner.net
October 8, 2026 at 12:36 PM
$LPCN — Health Canada approval of TLANDO drives LPCN stock surge, overshadowing long-term financial headwinds.
Health Canada approval of TLANDO for Canadian market.
https://market-scanner.net/tickers/LPCN.US
#ai #trading
Health Canada approval of TLANDO for Canadian market.
https://market-scanner.net/tickers/LPCN.US
#ai #trading
🟢 #$LPCN — Regulatory Approval
Health Canada Approves TLANDO for Testosterone Replacement Therapy
Health Canada approved TLANDO (oral testosterone undecanoate) for testosterone replacement therapy in adult males. This is an ex-U.S. regulatory approval, not an F…
https://biostock.app/symbols/LPCN
Health Canada Approves TLANDO for Testosterone Replacement Therapy
Health Canada approved TLANDO (oral testosterone undecanoate) for testosterone replacement therapy in adult males. This is an ex-U.S. regulatory approval, not an F…
https://biostock.app/symbols/LPCN
October 7, 2026 at 11:11 AM
🟢 #$LPCN — Regulatory Approval
Health Canada Approves TLANDO for Testosterone Replacement Therapy
Health Canada approved TLANDO (oral testosterone undecanoate) for testosterone replacement therapy in adult males. This is an ex-U.S. regulatory approval, not an F…
https://biostock.app/symbols/LPCN
Health Canada Approves TLANDO for Testosterone Replacement Therapy
Health Canada approved TLANDO (oral testosterone undecanoate) for testosterone replacement therapy in adult males. This is an ex-U.S. regulatory approval, not an F…
https://biostock.app/symbols/LPCN
🚨 #$LPCN +63% pre-market 💊
Health Canada OKs TLANDO; Verity to launch by year-end 🇨🇦
Wainwright: Neutral, $4 target. At $3.42, not much room left 🎯
$17M cap, still in the red. Set an exit, size small. @tipranks
Humble Trader | Gemini Trading
[NOT FINANCIAL ADVICE, DYOR!] #LPCN
Health Canada OKs TLANDO; Verity to launch by year-end 🇨🇦
Wainwright: Neutral, $4 target. At $3.42, not much room left 🎯
$17M cap, still in the red. Set an exit, size small. @tipranks
Humble Trader | Gemini Trading
[NOT FINANCIAL ADVICE, DYOR!] #LPCN
October 7, 2026 at 12:09 PM
Biotech Radar, October 7: an FDA pilot for Arrowhead, Parkinson’s data from Arvinas, Lipocine’s Canada approval and trial milestones at MAIA and RenovoRx.
https://www.merlintrader.com/biotech-radar-october-7-2026-arwr-arvn-lpcn-maia/
https://www.merlintrader.com/biotech-radar-october-7-2026-arwr-arvn-lpcn-maia/
Biotech Radar Oct 7, 2026: $ARWR $ARVN $LPCN $MAIA
October 7 biotech news: Arrowhead’s FDA pathway, Arvinas Parkinson’s data, Lipocine’s Canada approval, plus MAIA and RenovoRx trial milestones and risks.
www.merlintrader.com
October 7, 2026 at 5:29 PM
Biotech Radar, October 7: an FDA pilot for Arrowhead, Parkinson’s data from Arvinas, Lipocine’s Canada approval and trial milestones at MAIA and RenovoRx.
https://www.merlintrader.com/biotech-radar-october-7-2026-arwr-arvn-lpcn-maia/
https://www.merlintrader.com/biotech-radar-october-7-2026-arwr-arvn-lpcn-maia/
Latest company news, October 7: Lipocine announced that Health Canada approved TLANDO for testosterone replacement therapy in adult males.
Lipocine (#$LPCN): Can BLOOM Deliver a Clearer PPD Result?
www.merlintrader.com/lipocine-sto...
Lipocine (#$LPCN): Can BLOOM Deliver a Clearer PPD Result?
www.merlintrader.com/lipocine-sto...
Lipocine ($LPCN): BLOOM, Cash And The PPD Evidence
Lipocine and BLOOM: the next postpartum depression trial, prior Phase 3 results, cash use, TLANDO royalties and share dilution, with dated sources.
www.merlintrader.com
October 7, 2026 at 12:32 PM
Latest company news, October 7: Lipocine announced that Health Canada approved TLANDO for testosterone replacement therapy in adult males.
Lipocine (#$LPCN): Can BLOOM Deliver a Clearer PPD Result?
www.merlintrader.com/lipocine-sto...
Lipocine (#$LPCN): Can BLOOM Deliver a Clearer PPD Result?
www.merlintrader.com/lipocine-sto...
#LPCN Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
https://www.stocktitan.net/news/LPCN/lipocine-announces-health-canada-approval-of-tlando-for-testosterone-pjt8vwlfvj09.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LPCN/lipocine-announces-health-canada-approval-of-tlando-for-testosterone-pjt8vwlfvj09.html?utm_source=stocktitan-bluesky&utm_medium=social
Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
October 7, 2026 at 12:00 PM
#LPCN Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy
https://www.stocktitan.net/news/LPCN/lipocine-announces-health-canada-approval-of-tlando-for-testosterone-pjt8vwlfvj09.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LPCN/lipocine-announces-health-canada-approval-of-tlando-for-testosterone-pjt8vwlfvj09.html?utm_source=stocktitan-bluesky&utm_medium=social
$LPCN: Verity Pharma got Health Canada OK for TLANDO oral capsules for male hypogonadism. Canadian launch set for late 2026, boosting North American reach.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 10/07/26
export-download.canva.com
October 7, 2026 at 12:40 PM
$LPCN: Verity Pharma got Health Canada OK for TLANDO oral capsules for male hypogonadism. Canadian launch set for late 2026, boosting North American reach.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Lipocine (#$LPCN) says Health Canada approved TLANDO, its oral testosterone therapy for adult males with hypogonadism. Partner Verity plans a Canadian launch by year-end. No Canadian sales yet.
prismmarketview.com/lipocine-win...
prismmarketview.com/lipocine-win...
October 7, 2026 at 3:04 PM
Lipocine (#$LPCN) says Health Canada approved TLANDO, its oral testosterone therapy for adult males with hypogonadism. Partner Verity plans a Canadian launch by year-end. No Canadian sales yet.
prismmarketview.com/lipocine-win...
prismmarketview.com/lipocine-win...
Most searched small-cap stocks, Wed Oct 7th - #$NVTS #$INTR #$AMC #$PACB #$SDEV #$PFAI #$LPCN #$APUS #$LGCL #$WU #$WOLF #$QSI #$PENG #$MEC #$LAC #$HTZ #$DHT #$CYPH #$AMC #$ALT - More: crystalequityresearch.com/most-searche... - #smallcap
Most Searched, Wednesday October 7, 2026 – Crystal Equity Research
crystalequityresearch.com
October 7, 2026 at 10:07 PM
🚨 Premarket, Oct 7:
🟢 #$LPCN +48% as Health Canada OKs its TLANDO pill 💊
🔴 #$CRBU −36%: quits cell therapy, eyes a pivot
🔄 #$IPDN #$XHLD #$FRGT: Tuesday's pumps now dump
SPY −0.3%. Hype fades fast, so check news, size small. @benzinga
Humble Trader | Gemini Trading
[NOT FINANCIAL ADVICE, DYOR!]
🟢 #$LPCN +48% as Health Canada OKs its TLANDO pill 💊
🔴 #$CRBU −36%: quits cell therapy, eyes a pivot
🔄 #$IPDN #$XHLD #$FRGT: Tuesday's pumps now dump
SPY −0.3%. Hype fades fast, so check news, size small. @benzinga
Humble Trader | Gemini Trading
[NOT FINANCIAL ADVICE, DYOR!]
October 7, 2026 at 11:49 AM
🚨 $LPCN
Higuchi John W. () bought 25,007 shares at an average price of $2.2011 per common share. (Date: 2026-09-30)
Higuchi John W. () bought 25,007 shares at an average price of $2.2011 per common share. (Date: 2026-09-30)
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
October 2, 2026 at 12:28 AM
🚨 $LPCN
Higuchi John W. () bought 25,007 shares at an average price of $2.2011 per common share. (Date: 2026-09-30)
Higuchi John W. () bought 25,007 shares at an average price of $2.2011 per common share. (Date: 2026-09-30)
🚨 $LPCN
Higuchi John W. () bought 12,561 shares at an average price of $2.1600 per common share. (Date: 2026-09-28)
Higuchi John W. () bought 12,561 shares at an average price of $2.1600 per common share. (Date: 2026-09-28)
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
October 1, 2026 at 12:39 AM
🚨 $LPCN
Higuchi John W. () bought 12,561 shares at an average price of $2.1600 per common share. (Date: 2026-09-28)
Higuchi John W. () bought 12,561 shares at an average price of $2.1600 per common share. (Date: 2026-09-28)
Lipocine (#$LPCN): BLOOM Phase 3 Starts, First Dosing Early Q4
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/lipocine-sto...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/lipocine-sto...
September 23, 2026 at 11:50 AM
Lipocine (#$LPCN): BLOOM Phase 3 Starts, First Dosing Early Q4
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/lipocine-sto...
Free Biotech Catalyst Calendar on Merlintrader.
www.merlintrader.com/lipocine-sto...
🚨 $LPCN
On September 16, 2026, the Company presented at H.C. Wainwright 28 th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
On September 16, 2026, the Company presented at H.C. Wainwright 28 th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
September 16, 2026 at 8:39 PM
🚨 $LPCN
On September 16, 2026, the Company presented at H.C. Wainwright 28 th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
On September 16, 2026, the Company presented at H.C. Wainwright 28 th Annual Global Investor Conference which was being held September 14 – 16, 2026, in New York City, NY. A copy of the presentation is furnished as Exhibit 99.1 to this report and incorporated by reference herein.
🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
September 14, 2026 at 10:16 AM
🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
#LPCN Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
https://www.stocktitan.net/news/LPCN/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-t4qosxebqkxv.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LPCN/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-t4qosxebqkxv.html?utm_source=stocktitan-bluesky&utm_medium=social
Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.
www.stocktitan.net
September 14, 2026 at 12:00 PM
#LPCN Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression
https://www.stocktitan.net/news/LPCN/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-t4qosxebqkxv.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/LPCN/lipocine-announces-initiation-of-bloom-phase-3-study-of-lpcn-1154-t4qosxebqkxv.html?utm_source=stocktitan-bluesky&utm_medium=social
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression
Lipocine has announced the initiation of the BLOOM Phase 3 study for LPCN 1154, targeting postpartum depression treatment with promising oral therapies.
third-news.com
September 14, 2026 at 12:17 PM
Lipocine Launches Phase 3 BLOOM Study for LPCN 1154 to Combat Postpartum Depression#United_States#Salt_Lake_City#Lipocine#LPCN_1154#postpartum_depression
🚨 $LPCN
On September 8, 2026, Lipocine Inc. and A.G.P./Alliance Global Partners agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent will be up to 3.0%, subject to adjustment by the Company and the Sales Ag...
On September 8, 2026, Lipocine Inc. and A.G.P./Alliance Global Partners agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent will be up to 3.0%, subject to adjustment by the Company and the Sales Ag...
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
September 11, 2026 at 10:11 AM
🚨 $LPCN
On September 8, 2026, Lipocine Inc. and A.G.P./Alliance Global Partners agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent will be up to 3.0%, subject to adjustment by the Company and the Sales Ag...
On September 8, 2026, Lipocine Inc. and A.G.P./Alliance Global Partners agreed that the Sales Agent’s fee on sales made under that certain Sales Agreement dated April 26, 2024 between the Company and the Sales Agent will be up to 3.0%, subject to adjustment by the Company and the Sales Ag...
🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
SEC Filing: LPCN
Click to view the official SEC document.
www.sec.gov
September 10, 2026 at 10:14 AM
🚨 $LPCN
No valid summary extracted.
No valid summary extracted.
Lipocine to Showcase Innovations at 28th Annual Global Investment Conference#USA#New_York#Lipocine#LPCN#Oral_Therapeutics
Lipocine to Showcase Innovations at 28th Annual Global Investment Conference
Lipocine Inc. is set to present at the H.C. Wainwright 28th Annual Global Investment Conference, highlighting their pioneering oral therapeutics and engaging with investors.
third-news.com
September 10, 2026 at 12:24 PM
Lipocine to Showcase Innovations at 28th Annual Global Investment Conference#USA#New_York#Lipocine#LPCN#Oral_Therapeutics
Lipocine ($LPCN): A J&J Partnership Veteran Joins the Board as the FDA Guidance Meeting Is Set for Q3 2026
https://www.merlintrader.com/lipocine-stock-hub/
https://www.merlintrader.com/lipocine-stock-hub/
Lipocine ($LPCN): The Oral Brexanolone Rescue Thesis After A Failed Phase 3 | Merlintrader Trading Pub
Lipocine is no longer a clean “Phase 3 success into NDA” story. After the April 2026 failure in the full analysis set, the investment case has shifted into a more complicated, higher-risk regulatory recovery setup built around an outlier clinical site, post-hoc subgroup analyses, FDA feedback, a possible validation study and the value of an oral, at-home brexanolone profile in postpartum depression.
www.merlintrader.com
September 6, 2026 at 12:53 AM
Lipocine ($LPCN): A J&J Partnership Veteran Joins the Board as the FDA Guidance Meeting Is Set for Q3 2026
https://www.merlintrader.com/lipocine-stock-hub/
https://www.merlintrader.com/lipocine-stock-hub/